




PHARMACEUTICAL 2021

Adamas Pharmaceuticals Inc
Rank 334 of 402





PHARMACEUTICAL 2021

Adamas Pharmaceuticals Inc Rank 334 of 402

The relative strengths and weaknesses of Adamas Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Adamas Pharmaceuticals Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 33% points. The greatest weakness of Adamas Pharmaceuticals Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 163% points.

The company's Economic Capital Ratio, given in the ranking table, is -99%, being 146% points below the market average of 47%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 111,736 |
| Cost of Goods Sold | 2,038 |
| Intangible Assets | 0 |
| Liabilities, Current | 34,867 |
| Liabilities, Non-Current | 135,138 |
| Other Assets | 6,695 |
| Other Compr. Net Income | -16 |
| Other Expenses | 13,239 |
| Other Liabilities | 0 |
| Other Net Income | 0 |
| Other Revenues | 74,461 |
| Property and Equipment | 1,598 |
| Research and Development | 9,746 |
| Selling, General and Administrative Expense | 106,841 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 120,029 |
| Liabilities | 170,005 |
| Expenses | 131,864 |
| Revenues | 74,461 |
| Stockholders Equity | -49,976 |
| Net Income | -57,403 |
| Comprehensive Net Income | -57,411 |
| Economic Capital Ratio | -99% |